Chromosome fragility in the Lennox-Gastaut epilepsy syndrome.
Chromosome fragility was sought in a well-defined cohort of patients with Lennox-Gastaut epilepsy syndrome. Twenty-five patients plus 25 age- and sex-matched normal controls had cytogenetic studies performed. All patients were taking sodium valproate, and four were also on hydantoin. Blood cultures from both patients and controls were set up simultaneously in an appropriate medium designed to elicit fragile-sites. Harvesting took place after 96 h by standard techniques. In addition to routine banded analysis, at least 50 cells were scored for chromosome breaks and gaps from each patient and control. Results showed no difference between the patients and the control group in the overall occurrence of fragility or the type of aberration detected. No fragile-X syndrome was detected. This study found no effect due to sodium valproate on the occurrence of chromosome aberrations.
Smith
A
A
Cytogenetics Unit, Oliver Latham Laboratory, Sydney, Australia.
Beran
R G
RG
D000293:Adolescent; D000328:Adult; D002869:Chromosome Aberrations; D002871:Chromosome Banding; D043283:Chromosome Fragile Sites; D002873:Chromosome Fragility; D015331:Cohort Studies; D004827:Epilepsy / Q000097:blood / Q000188:drug therapy / Q000235:genetics*; D005260:Female; D006801:Humans; D007621:Karyotyping; D008297:Male; D014635:Valproic Acid / Q000009:adverse effects / Q000627:therapeutic use
D014635:Valproic Acid